Health authorities are adopting a 'Low-to-Moderate' risk posture for semaglutide and tirzepatide, based on their proven weight loss effectiveness and ancillary health benefits. While recent data indicate robust outcomes—averaging over 4 kg in weight loss and modest HbA1c reductions—emerging concerns regarding ocular and reproductive safety necessitate targeted pharmacovigilance. This stance reflects a commitment to patient safety amid rising prescription rates, indicating a pivotal moment in obesity management.
Title not available for this citation.
“GLP-1RA treatment was associated with a body weight reduction of 4.31 kg (95% CI: 3.61-5.00 kg).”
Title not available for this citation.
“GLP-1RA treatment was associated with a HbA1c reduction of 0.25% (95% CI: 0.18-0.32%).”
Title not available for this citation.
“These findings provide evidence that GLP-1RAs can be effectively and safely used as adjunctive therapy to insulin in people with T1D.”
Title not available for this citation.
“In 2024, a second brand of injectable semaglutide was marketed, authorized for the indication of weight loss, along with the first tirzepatide. Both are indicated as an adjunct to a low-calorie diet and increased physical activity for weight control, including weight loss and maintenance, in adults with a BMI greater than 27.”
Title not available for this citation.
“The main objective of the research will be to assess the results obtained over one year regarding weight loss in patients treated with semaglutide or tirzepatide, as well as adverse effects and, where applicable, rebound effect, and to compare them with the results obtained in other patients from the nutrition service who are not receiving these treatments.”
Title not available for this citation.
“Data collection will take place during 2026 through various questionnaires and/or interviews with patients who agree to participate in the study.”
Title not available for this citation.
“Those initiated on GLP1-RA had a significant reduction in median weight, from 131.0 (118.7-149.6) kg at baseline to 120.0 (109.2-135.3) kg at 12 months, p < 0.001.”
Title not available for this citation.
“Among 666 participants, 59 (9%) were on GLP1-RA at baseline.”
Title not available for this citation.
“GLP-1RA use was also associated with decreased risk at 5 (RR: 0.605), 7 (RR: 0.499), and 10 (RR: 0.437) years compared to no drug use.”
Title not available for this citation.
“Conversely, OWLD use was associated with increased risk at 5 (RR: 2.142), 7 (RR: 2.093) and 10 (RR: 2.111) years compared to no drug use.”
Title not available for this citation.
“Tirzepatide was extracted from rat plasma by protein precipitation using methanol.”
Title not available for this citation.
“The validated method was successfully applied to a pharmacokinetic study in rats following the intravenous and subcutaneous injection of tirzepatide at 0.3 mg/kg.”